Clinical efficacy and predictive indicators of cindilizumab combined with XELIRI protocol in advanced colorectal carcinoma patients
Cindilizumab combined with XELIRI regimen improves ORR and DCR in patients with advanced colorectal cancer but may increase the risk of hypothyroidism and renal impairment. CEA, tumor diameter, KRAS/NRAS gene, and treatment regimen are independent predictors of treatment response. The combined predictive model demonstrates robust diagnostic performance.
Authors
- Weiwei Liu (ORCID: https://orcid.org/0000-0001-5069-9727)
Institutions
- Microbiology Institute of Shaanxi (CN)
Publication Details
- Journal
- American Journal of Translational Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/kzdr9031
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00